


Linrodostat

Chemical Properties

CAS No. :	1923833-60-6
Formula:	C ₂₄ H ₂₄ ClFN ₂ O
Molecular Weight:	410.91
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Linrodostat (BMS-986205) is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).
Targets(IC50)	IDO, Indoleamine 2,3-Dioxygenase (IDO)
In vitro	BMS-986205 shows potent inhibition of kynurenine production in IDO1-HEK293 cells (IC50: 1.1 nM) but not in TDO-HEK293 cells[1].

Solubility Information

Solubility	Ethanol: 15 mg/mL (36.5 mM), Sonication is recommended. DMSO: 50 mg/mL (121.68 mM), Sonication is recommended. H ₂ O: Insoluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.87 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4336 mL	12.1681 mL	24.3362 mL
5 mM	0.4867 mL	2.4336 mL	4.8672 mL
10 mM	0.2434 mL	1.2168 mL	2.4336 mL
50 mM	0.0487 mL	0.2434 mL	0.4867 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481